September 17, 2025
Aneurisk Announces Scientific Advisory Board Featuring Pioneers and Global Leaders in Vascular Surgery, Computational Medicine, and Healthcare Innovation
PITTSBURGH, PA - Aneurisk, Inc., a University of Pittsburgh-licensed startup company dedicated to improving outcomes for patients with arterial aneurysms through advanced analytics and AI-enabled software, has announced the formation of its Scientific Advisory Board (SAB).
The SAB brings together leaders in vascular surgery, computational modeling applications in medicine, and healthcare innovation who will help shape Aneurisk’s clinical, regulatory, and commercialization strategies. The members of the Aneurisk Advisory Board are:
Charles Taylor, PhD. Dr. Taylor is a globally recognized pioneer and leader in predictive simulation-based medicine and artificial intelligence. He co-founded HeartFlow in 2007 where he previously served as Chief Technology Officer, Chief Scientific Officer, and as a member of the Board of Directors until the company’s IPO this August. Under his leadership, HeartFlow revolutionized the field by successfully bringing to market the first AI-enabled coronary blood-flow simulation included in clinical guidelines and used widely today. Dr. Taylor was elected to the National Academy of Engineering in 2024 for his contributions to predictive simulation in cardiovascular care and now serves as the W. A. “Tex” Moncrief, Jr. Chair in Computational Medicine at the Oden Institute at the University of Texas at Austin.
John Kalafut, PhD. Dr. Kalafut is a widely recognized expert and sought-after consultant in regulatory strategy and healthcare AI and is the co‑founder and CEO of Asher Orion Group. Dr. Kalafut has a robust knowledge of AI/ML strategy, product development, digital transformation, and regulatory pathways based on his previous experience at GE Healthcare as Chief Scientist of Digital Research responsible for digital scientific affairs. Dr. Kalafut holds 40+ US patents and is an inventor on a significant number of medical imaging and diagnostic innovations which continue to see use today.
Ronald Dalman, MD. Dr. Dalman is the Walter C. and Elsa R. Chidester Professor of Surgery and the Chief Emeritus of the Division of Vascular Surgery at Stanford University which he led from 2005 to 2021. He is an internationally acclaimed surgeon-scientist whose contributions to vascular surgery and the understanding and treatment of aortic pathophysiology as a clinician, researcher, and leader are unparalleled. Among other notable achievements, he served as the President of the Society for Vascular Surgery, the specialty’s premier national society, from 2020-2021, and continues to contribute deeply to vascular research, surgical education, and governance.
“Aneurisk’s vision is to improve aneurysm disease management by delivering tools that empower clinicians, support patient-specific decision making, and ultimately improve patient outcomes,” said Nathan Liang, MD, Co-founder & CEO of Aneurisk. “The experience and insight of these three scientific advisors will be invaluable in guiding us toward that future.”
Aneurisk’s strategy centers on three pillars:
-
Working hand-in-hand with physicians to ensure technology directly supports patient care.
-
Building evidence-driven solutions grounded in scientific rigor and robust clinical validation.
-
Accelerating adoption by integrating seamlessly into healthcare workflows and ensuring broad accessibility.
“Each of these scientific advisors were selected based on where we felt gaps previously existed in our team,” said David Vorp, PhD, Co-founder & CSO of Aneurisk. “The formation of this Scientific Advisory Board positions Aneurisk to advance its mission of redefining how life-threatening aneurysms are understood, monitored, and managed.”
For more information about Aneurisk, visit www.aneurisk.ai.
Media Contact:
Micah Guffey
Chief Operating Officer
guffey@aneurisk.ai